Biogen, Eisai unveil new data on lecanemab, but questions linger on ARIA-E; Spatial biology outfit grabs $33M round
Eisai and Biogen have released more data on lecanemab, another anti-Alzheimer’s drug in the partnership that spawned aducanumab. However, questions about the data remain when looking at ARIA-E events, with the typical caveat of cross-trial comparisons.
The data from lecanemab’s Phase IIb study were presented at the annual AD/PD meeting, and the ratio of ARIA-E — a type of amyloid-related imaging abnormalities resulting in brain bleeds — appeared higher than in Aduhelm studies when compared to placebo. Two trials on the highly controversial drug, ENGAGE and EMERGE, showed an ARIA-E rate of 41%, compared to 10% in the placebo arm. That was a 4:1 ratio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.